Francis E. Odonnell, Jr. Sells 8,000 Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Stock

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Francis E. Odonnell, Jr. sold 8,000 shares of BioDelivery Sciences International stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $6.86, for a total transaction of $54,880.00. Following the completion of the transaction, the director now directly owns 564,754 shares of the company’s stock, valued at approximately $3,874,212.44. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of BDSI stock traded down $0.06 during midday trading on Wednesday, hitting $6.70. 1,116,894 shares of the company were exchanged, compared to its average volume of 974,221. The firm has a market capitalization of $605.16 million, a P/E ratio of -9.18 and a beta of 0.49. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.02 and a current ratio of 2.25. The firm’s 50 day moving average price is $5.91 and its two-hundred day moving average price is $4.74. BioDelivery Sciences International, Inc. has a 52 week low of $2.80 and a 52 week high of $7.01.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its earnings results on Tuesday, November 12th. The specialty pharmaceutical company reported $0.33 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.34. The business had revenue of $30.31 million during the quarter, compared to the consensus estimate of $28.86 million. BioDelivery Sciences International had a negative net margin of 22.11% and a negative return on equity of 8.80%. Analysts expect that BioDelivery Sciences International, Inc. will post 0.02 EPS for the current year.

BDSI has been the subject of a number of analyst reports. William Blair reissued a “buy” rating on shares of BioDelivery Sciences International in a research report on Tuesday, September 17th. Janney Montgomery Scott reissued a “buy” rating on shares of BioDelivery Sciences International in a research report on Wednesday, November 13th. BidaskClub raised shares of BioDelivery Sciences International from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 16th. TheStreet raised shares of BioDelivery Sciences International from a “d” rating to a “c” rating in a research report on Friday, November 22nd. Finally, ValuEngine raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Tuesday. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $6.50.

Hedge funds have recently made changes to their positions in the stock. Mackay Shields LLC boosted its holdings in BioDelivery Sciences International by 65.7% in the 3rd quarter. Mackay Shields LLC now owns 605,900 shares of the specialty pharmaceutical company’s stock valued at $2,551,000 after purchasing an additional 240,200 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in BioDelivery Sciences International by 1,019.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 186,409 shares of the specialty pharmaceutical company’s stock valued at $867,000 after purchasing an additional 169,757 shares during the period. Los Angeles Capital Management & Equity Research Inc. bought a new stake in BioDelivery Sciences International in the 2nd quarter valued at about $1,395,000. River & Mercantile Asset Management LLP bought a new stake in BioDelivery Sciences International in the 2nd quarter valued at about $1,860,000. Finally, Northern Trust Corp boosted its holdings in BioDelivery Sciences International by 39.8% in the 2nd quarter. Northern Trust Corp now owns 258,748 shares of the specialty pharmaceutical company’s stock valued at $1,203,000 after purchasing an additional 73,637 shares during the period. 69.44% of the stock is owned by institutional investors and hedge funds.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Read More: How a Strangle Strategy is different from a Straddle Strategy

Insider Buying and Selling by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.